Prostate and other male cancers:
Indications for NUBEQA:
Non-metastatic, castration-resistant prostate cancer.
Swallow whole. Take with food. 600mg twice daily. Give concurrent GnRH analog or patient should have had bilateral orchiectomy. Severe renal impairment (eGFR 15–29mL/min/1.73m2) not on hemodialysis: 300mg twice daily. Moderate hepatic impairment (Child-Pugh Class B): 300mg twice daily. Dose modification: see full labeling.
Embryo-fetal toxicity. Advise males (w. female partners of reproductive potential) to use effective contraception during and for 1 week after last dose.
Androgen receptor inhibitor.
Antagonized by combined P-gp and strong or moderate CYP3A4 inducers; avoid. Potentiated by combined P-gp and strong CYP3A4 inhibitors; monitor and adjust dose. Avoid concomitant use with BCRP substrates; if unavoidable, monitor and consider dose reduction of the substrate drug. May potentiate OATP1B1 or OATP1B3 substrates; monitor and consider dose reduction of these drugs.
Fatigue, pain in extremity, rash; ischemic heart disease, heart failure, lab abnormalities (increased AST and bilirubin, decreased neutrophil count).
Generic Drug Availability: